Maravai LifeSciences Holdings, Inc. (MRVI)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$6.98-9.59%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · MRVI
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -57.6% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 6.7% |
Growth built into the price is above our model estimate.
The price assumes 64.2 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 66 industry peers · Company calendar date is not available
MRVI — earnings in line
Dated 2026-08-06
of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.
Why it matters: Maravai raised its profit target after two quarters of positive Adjusted EBITDA. Meeting it would show that gains are lasting.
Supportive ifFull-year 2026 Adjusted EBITDA is at least $33M and no more than $35M.
Worry ifFull-year Adjusted EBITDA falls below $33M, or the company cuts its $33M–$35M range.
Why it matters: More active customers may add to future sales as their drug programs advance. Flat customer counts would weaken that signal.
Supportive ifMaravai reports more than 125 active ModTail customers. It also reports more customers or higher sales.
Worry ifThe active ModTail customer count stays at or below 125, or Maravai reports that the count fell.
Why it matters: Maravai kept its 2026 revenue range after Q2. Results within the range would support its growth plan.
Supportive ifFull-year 2026 revenue lands at or above $205M, with TriLink and Cygnus both growing year over year.
Worry ifFull-year revenue is below $205M, or either segment reports a year-over-year drop.
Why it matters: The refinancing cut debt and moved the loan due date to 2032. Stable debt would support the stated plan to keep a stronger balance sheet.
Supportive ifA later filing shows term debt at or below $150M, with the loan still due in June 2032.
Worry ifA later filing shows term debt above $150M from new borrowing, or a change that shortens the June 2032 maturity.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$280 on $10,000 · ±2.8% | How much price usually moves either way. |
| Bad day | $658 loss on $10,000 · 6.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,960 loss on $10,000 · 29.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.